Pembrolizumab (Keytruda)
Canadian Journal of Health Technologies · 13.03.2026 · 6 (3)
DOI: 10.51731/cjht.2026.1382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 13.03.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda), 100 mg/4 mL vial, solution for infusion. Indication: For the treatment of adult patients with HNSCC whose tumours express PD-L1 (CPS ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with RT with or without cisplatin and then as monotherapy.
Zitieren
APA
CDA-AMC (2026). Pembrolizumab (Keytruda). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1382
Vancouver
CDA-AMC. Pembrolizumab (Keytruda). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1382
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Pembrolizumab (Keytruda)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {3},
doi = {10.51731/cjht.2026.1382}
}
EUVIMED